Real-World Comparative Outcomes of First-Line (1L) Venetoclax + Obinutuzumab (VenO) Versus Covalent Bruton's Tyrosine Kinase Inhibitors (BTKis) ± Anti-CD20 Therapy Among Patients With Chronic Lymphocytic Leukemia (CLL) in the United States (US)

Saved in:
Bibliographic Details
Published inClinical lymphoma, myeloma and leukemia Vol. 24; p. S182
Main Authors Li, Sophia S., Ravelo, Arliene, Schuldt, Robert, Shahkarami, Mina, Thompson, Meghan C.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.09.2024
Online AccessGet full text

Cover

More Information
ISSN:2152-2650
DOI:10.1016/S2152-2650(24)00587-1